PMID- 24876916
OWN - NLM
STAT- MEDLINE
DCOM- 20141228
LR  - 20211021
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2014
DP  - 2014
TI  - Lipid and protein oxidation in newborn infants after lutein administration.
PG  - 781454
LID - 10.1155/2014/781454 [doi]
LID - 781454
AB  - OBJECTIVES: To test the hypothesis that neonatal supplementation with lutein in 
      the first hours of life reduces neonatal oxidative stress (OS) in the immediate 
      postpartum period. METHODS: A randomized controlled, double-blinded clinical 
      trial was conducted among 150 newborns divided into control group, not 
      supplemented (n = 47), and test group, supplemented with lutein on the first day 
      postpartum (n = 103). Blood Samples were collected at birth from cord and at 
      48 hrs postpartum while routine neonatal metabolic screenings were taking place. 
      Total hydroperoxide (TH), advanced oxidation protein products (AOPP), and 
      biological antioxidant potential (BAP) were measured by spectrophotometry and 
      data were analyzed by Wilcoxon rank sum test and by multivariate logistic 
      regression analysis. RESULTS: Before lutein supplementation, the mean blood 
      concentrations of AOPP, TH, and BAP were 36.10 umol/L, 156.75 mmol/H2O2, and 
      2361.04 umol/L in the test group. After lutein supplementation, significantly 
      higher BAP increment (0.17 +/- 0.22 versus 0.06 versus +/- 0.46) and lower TH 
      increment (0.46 +/- 0.54 versus 0.34 +/- 0.52) were observed in the test group 
      compared to controls. CONCLUSION: Neonatal supplementation with lutein in the 
      first hours of life increases BAP and reduces TH in supplemented babies compared 
      to those untreated. The generation of free radical-induced damage at birth is 
      reduced by lutein. This trial is registered with ClinicalTrials.gov NCT02068807.
FAU - Perrone, S
AU  - Perrone S
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Tei, M
AU  - Tei M
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Longini, M
AU  - Longini M
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Santacroce, A
AU  - Santacroce A
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Turrisi, G
AU  - Turrisi G
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Proietti, F
AU  - Proietti F
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Felici, C
AU  - Felici C
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Picardi, A
AU  - Picardi A
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Bazzini, F
AU  - Bazzini F
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
FAU - Vasarri, P
AU  - Vasarri P
AD  - Division of Neonatology, New Clinical Hospital of Prato, Via Suor Niccolina 
      Infermiera 20, Galciana, 59100 Prato, Italy.
FAU - Buonocore, G
AU  - Buonocore G
AD  - Neonatal Care Unit, Department of Molecular and Developmental Medicine, 
      University Hospital of Siena, Viale M. Bracci 16, 53100 Siena, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT02068807
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140430
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Advanced Oxidation Protein Products)
RN  - 0 (Antioxidants)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - X72A60C9MT (Lutein)
SB  - IM
MH  - Advanced Oxidation Protein Products/blood
MH  - Antioxidants/analysis/chemistry/metabolism
MH  - Area Under Curve
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrogen Peroxide/blood
MH  - Infant, Newborn
MH  - Lipid Peroxidation/drug effects
MH  - Logistic Models
MH  - Lutein/*pharmacology
MH  - Male
MH  - Oxidative Stress/*drug effects
MH  - ROC Curve
MH  - Spectrophotometry
PMC - PMC4021681
EDAT- 2014/05/31 06:00
MHDA- 2014/12/30 06:00
PMCR- 2014/04/30
CRDT- 2014/05/31 06:00
PHST- 2014/02/24 00:00 [received]
PHST- 2014/04/11 00:00 [revised]
PHST- 2014/04/14 00:00 [accepted]
PHST- 2014/05/31 06:00 [entrez]
PHST- 2014/05/31 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
PHST- 2014/04/30 00:00 [pmc-release]
AID - 10.1155/2014/781454 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2014;2014:781454. doi: 10.1155/2014/781454. Epub 2014 Apr 
      30.